Design and development of novel EGFR inhibitors spanning all subgroups of EGFR mutations in non-small cell lung cancer.

Authors

Caolin Wang, Yiting Cen, Manzhan Zhang, Jiahong Tang, Zitong Yan, Lijuan Xie, Deheng Sun, Wei Zhou, Jie Wang, Panpan Yu, Zhen Yuan, Junyi Wang, Zeyan Hu, Tingyuan Yang, Wenjie Sha, Shiliang Li, Zhenjiang Zhao, Yufang Xu, Zhuo Chen, Honglin Li

Published in

Innovation (Cambridge (Mass.)). Volume 7. Issue 7. Pages 101313. Jul 06, 2026. Epub Feb 12, 2026.

Abstract

EGFR mutations are common in non-small cell lung cancer (NSCLC), with classical mutations (L858R and exon 19 deletions [Ex19del]) and T790M mutation responsive to three generations of EGFR inhibitors (TKIs). However, the other 30% EGFR mutations, which are classified into exon 20 insertions (Ex20ins) and PACC (P loop/αC-helix compressing) often confer resistance to current TKIs, thereby inducing limited clinical efficacy. In this article, a conserved subpocket behind the ATP-binding domain was detected with our precursor from in-house virtual screening and structural superposition against all subgroups of mutations. This subpocket was utilized combining with traditional ATP pocket in the design and optimization of pan-EGFR inhibitors. The representative compound ZW-49 could potently inhibit all subgroups of EGFR mutations with selectivity over wild-type EGFR and other target families. By means of in silico simulations, we further elucidate the key sites within the subpocket that significantly contribute to the binding of the Ex20ins and PACC mutations with ZW-49. Furthermore, ZW-49 could efficiently induce tumor regression in multiple xenograft models. Deuterated derivatives of ZW-49 were designed by predicting and modifying the sites of metabolism that exhibited improved PK properties while retaining inhibition activities against all subgroups of EGFR mutations. Our work suggests a pan-EGFR inhibitor development strategy to address EGFR mutational heterogeneity for NSCLC including structure-based drug design and metabolic optimization. We also provided ZW-49 as a promising pan-EGFR inhibitor, currently in phase 1 clinical trials (CTR20212743).

PMID:
42422019
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.